AUSTIN, Texas, February 19, 2019 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM), a medical-stage oncology organization targeted at the discovery and improvement of the organization’s proprietary engineered toxin our bodies (ETBs), which might be differentiated, focused, biologic therapeutics for cancer, today announced the appointment of Roger J. Waltzman, M.D., as Chief Medical Officer, effective Tuesday, February 19, 2019. Dr. Waltzman will record to Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates, and may be liable for all scientific development and regulatory activities.
“Roger has an incredible tune record in leading the scientific development of successful oncology pills, having performed major roles in developing merchandise which include Glivec® and Jakafi®, and we’re excited to welcome him to our group as Chief Medical Officer,” said Eric Poma, Ph.D., Chief Executive and Chief Scientific Officer of Molecular Templates. “Roger’s experience in handling each early and late-stage clinical program, overseeing a regulatory success packages, and supervising expert research groups might be precious as we advance our pipeline of novel oncology applicants.”
“I am excited to enroll in Molecular Templates, a employer that is at the vanguard of oncology drug development. I agree that its ETB platform represents one of the maximum exciting oncology technology enterprise-extensive,” said Dr. Waltzman. “I look forward to main our scientific improvement team in the direction of developing novel tablets for cancer and increasing treatments alternatives for oncology sufferers.”
Dr. Waltzman is a board-certified clinical oncologist with over twenty years of revel in the pharmaceutical and biotechnology industries and clinical practice/academia. His profession highlights consist of 9 years in senior drug development roles at Novartis Pharmaceuticals Corporation and six years in positions of increasing duty at Novartis Oncology (2007–2013). He played a primary function in improving extraordinarily a success Novartis branded oncology drugs, Glivec® (imatinib) and Jakafi® (ruxolitinib). His final part at Novartis changed into Executive Director and Full Development Head of Malaria Drug Development (2013-16). More recently, Dr. Waltzman changed into CMO at Rgenix, in which he supervised the development of immuno-oncology and metabolic inhibitor belongings through Phase 1 a/b. Previously, he served as CMO and CSO at Jaguar Health and Napo Pharmaceuticals, in which he led medical aspects of improvement and commercialization of Mytesi® (crofelemer) for patients with HIV and diarrhea, as well as improvement applications in chemotherapy-brought on diarrhea and numerous warning signs for partner and manufacturing animals.
Before becoming a member of industry, Dr. Waltzman held assistant professorships in clinical oncology and palliative care at Saint Vincent’s Hospital and Mount Sinai School of Medicine in New York. At Saint Vincent’s Hospital, he became responsible for overseeing oncology care for sufferers with breast, gastrointestinal, gynecologic, thoracic, and AIDS-related malignancies. He completed his fellowship in hematology/oncology at Memorial Sloan Kettering Cancer Center. Dr. Waltzman earned an M.B.A. At Columbia Business School where he graduated valedictorian, an M.D. From Brown University School of Medicine and a B.A. From Brown University.